Table 2 Clinical characteristics concerning psychiatric disorders at baseline
Patients (N = 144) | Group A | Group B | p-value | |
|---|---|---|---|---|
Types of psychiatric illnesses,n(%) | 101 (70.1) | 43 (29.9%) | ||
Anxiety disordersa | 48 (33.3%) | |||
Mood disordersb | 53 (36.8%) | |||
Psychotic disorder | 43 (29.9%) | |||
Duration psychiatric illness, years (range) | 9 (6–13) | 8 (6.5–12.5) | 12 (8–15.5) | 0.011 |
Suicide attempted,n(%) | 5 (3.5%) | 2 (2%) | 3 (7%) | 0.157 |
Psychiatric treatment modification before DAA treatment,n(%) | 20 (13.9%) | 11 (10.9%) | 9 (21%) | 0.121 |
Opioid substitution treatment,n(%) | 12 (8.3%) | 2 (2%) | 10 (23.3%) | < 0.001 |
Methadone | 11 (7.6%) | 1 (1%) | 10 (23.3%) | < 0.001 |
Buprenorphine | 1 (0.7%) | 1 (1%) | 0 | 1.000 |
Referred alcohol consumption,n(%) | 5 (3.5%) | 4 (4%) | 1 (2.3%) | 1.000 |